Human Immune Response to Botulinum Pentavalent (ABCDE) Toxoid, Determined by a Neutralization Test and by an ELISA
Abstract
To determine the immune status of persons receiving Botulinum Pentavalent (ABCDE) Toxoid and to evaluate the effectiveness of the vaccine, we surveyed immunized individuals for neutralizing antibodies to type A and to type B botulinum toxins. Just prior to the first annual booster, 10 to 21 people (48%) and 14 of 21 (67%) lacked a detectable titer for type A and type B, respectively. After the first booster, all individuals tested had a demonstrable titer to both types A and B. There was a wide range of antibody levels among individuals at the same point in the immunization scheme. Results from an ELISA, with purified type A or type B neurotoxin as the capture antigen, were compared to neutralization test results on 186 serum samples for type A and 168 sera for type B. Due to the wide dipersion of values obtained, using ELISA test results to predict neutralizing antibody levels is unwarranted. Keywords: Bioassay, ELISA.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 04, 1988
- Accession Number
- ADA197882
Entities
People
- Lynn S. Siegel
Organizations
- United States Army Medical Research Institute of Infectious Diseases